<p>M&amp;T Bank Corp 在最近向证券交易委员会提交的文件中表示，在第四季度将其在联合治疗公司（NASDAQ:UTHR - 免费报告）的持股比例提高了 171.6%。该公司在此期间购买了 1,985 股后，持有这家生物技术公司的 3,142 股股票。M&amp;T Bank Corp 在联合治疗公司的持股在最近一个季度末价值为 1,531,000 美元。</p>
<ul>
<li>全球最大对冲基金的三大股票推荐</li>
</ul>
<p>其他机构投资者和对冲基金最近也买卖了该公司的股票。威尔明顿储蓄基金协会 FSB 在第三季度将其在联合治疗公司的持股提高了 125.6%。威尔明顿储蓄基金协会 FSB 现在拥有 88 股这家生物技术公司的股票，价值 37,000 美元，此前在此期间又购买了 49 股。哈伯资本顾问公司在第四季度购买了价值约 48,000 美元的联合治疗新股份。Abich Financial Wealth Management LLC 在第三季度购买了价值约 44,000 美元的联合治疗新股份。WealthCollab LLC 在第二季度将其在联合治疗公司的持股提高了 55.9%。WealthCollab LLC 现在拥有 106 股这家生物技术公司的股票，价值 30,000 美元，此前在此期间又购买了 38 股。最后，乐天证券公司在第二季度将其在联合治疗公司的持股提高了 76.7%。乐天证券公司现在拥有 106 股这家生物技术公司的股票，价值 30,000 美元，此前在此期间又购买了 46 股。目前 94.08% 的股票由对冲基金和其他机构投资者持有。</p>
<p>获取 <strong>联合治疗</strong> 的提醒：</p>
<h2>联合治疗的关键新闻</h2>
<p>以下是本周影响联合治疗的关键新闻：</p>
<ul>
<li>积极情绪：投资者关注联合治疗的产品管线和增长催化剂，尤其是关于 IPF 的积极 Tyvaso 数据和对 ralinepag 的巨大潜力的乐观情绪，这可能支持未来的收入增长。UTHR 第一季度业绩未达预期，股价因强劲前景而上涨</li>
<li>积极情绪：加拿大皇家银行维持 <strong>跑赢大盘</strong> 的评级，仅将其目标价从 707 美元略微下调至 701 美元，表明对当前水平的上行潜力仍然充满信心。RBC 下调 UTHR 的目标价</li>
<li>中性情绪：联合治疗召开了 2026 年第一季度的财报电话会议，投资者可能会关注关于 Tyvaso、ralinepag 和公司的增长前景的评论。2026 年第一季度财报电话会议记录</li>
<li>消极情绪：第一季度业绩未达预期，EPS 为 5.82 美元，低于预期的 7.00 美元，收入为 7.815 亿美元，低于预期的 7.974 亿美元；收入同比下降 1.6%。2026 年第一季度财务结果</li>
<li>消极情绪：内部人士的卖出可能对情绪造成压力：首席执行官 Martine Rothblatt 卖出了 9,500 股，执行副总裁 Paul Mahon 卖出了 8,300 股，均为其持股的显著减少。Rothblatt SEC 文件 Mahon SEC 文件</li>
</ul>
<h2>联合治疗股票表现</h2>
<ul>
<li>Liquidia：法院胜利是行业巨头的觉醒？</li>
</ul>
<p>UTHR 股票在周五开盘价为 564.94 美元。该公司的 50 日移动平均价格为 550.17 美元，200 日移动平均价格为 501.37 美元。联合治疗公司的 52 周低点为 272.12 美元，52 周高点为 609.35 美元。该公司的市值为 239.8 亿美元，市盈率为 20.85，PEG 比率为 1.77，贝塔值为 0.60。</p>
<p>联合治疗（NASDAQ:UTHR - 获取免费报告）最近于 5 月 6 日发布了其财报。该生物技术公司报告第一季度每股收益为 5.82 美元，低于分析师一致预期的 7.00 美元（差额为 1.18 美元）。联合治疗的股本回报率为 19.24%，净利润率为 40.62%。该公司第一季度的收入为 7.815 亿美元，而分析师预期为 7.974 亿美元。在去年同期，该公司每股收益为 6.63 美元。该公司的季度收入同比下降 1.6%。股票分析师预测联合治疗公司在当前财年将发布 27.4 的每股收益。</p>
<h2>分析师评级变动</h2>
<ul>
<li>分析师表示这两家中型生物技术公司具有 2 倍潜力</li>
</ul>
<p>UTHR 一直是几份研究分析报告的主题。摩根士丹利在周四的报告中对联合治疗的股票设定了 516.00 美元的目标价。HC Wainwright 在 3 月 31 日的报告中将联合治疗的目标价从 600.00 美元提高至 660.00 美元，并给予该公司 “买入” 评级。美国银行在 3 月 31 日的研究报告中将联合治疗的目标价从 569.00 美元提高至 626.00 美元，并给予该股票 “中性” 评级。TD Cowen 在 3 月 30 日的研究报告中将联合治疗的目标价从 575.00 美元提高至 660.00 美元，并给予该股票 “买入” 评级。最后，瑞银集团在 3 月 5 日的研究报告中将联合治疗的目标价从 655.00 美元提高至 705.00 美元，并给予该股票 “买入” 评级。十一位投资分析师对该股票给予了买入评级，两位分析师对该公司的股票给予了持有评级。根据 MarketBeat，该股票的平均评级为 “适度买入”，共识目标价为 619.42 美元。</p>
<p><strong>阅读我们关于 UTHR 的最新分析</strong></p>
<h2>内部人士买卖情况</h2>
<p>在相关消息中，首席财务官 James Edgemond 于 3 月 23 日星期一出售了 10,000 股公司的股票，交易平均价格为 527.48 美元，总价值为 5,274,800.00 美元。交易完成后，首席财务官直接持有 18,876 股公司的股票，价值为 9,956,712.48 美元。这代表其持股比例减少了 34.63%。此次出售在向 SEC 提交的文件中披露，相关文件可通过此链接获取。此外，首席运营官 Michael Benkowitz 于 2 月 9 日星期一出售了 22,500 股公司的股票，平均售价为 474.65 美元，总价值为 10,679,625.00 美元。SEC 对此次出售的文件提供了更多信息。在过去的九十天里，内部人士出售了 485,155 股公司股票，价值为 266,370,949 美元。目前，10.30% 的股票由公司内部人士持有。</p>
<h2>关于联合治疗</h2>
<p>(免费报告)</p>
<p>联合治疗公司 NASDAQ: UTHR 是一家生物技术公司，致力于开发和商业化独特产品，以应对危及生命的疾病。该公司的主要关注点是肺动脉高压（PAH），已推出多种疗法，旨在改善患者的功能能力和生活质量。其市场产品包括持续输注特瑞普利（Remodulin）、吸入特瑞普利（Tyvaso）、口服特瑞普利（Orenitram）和他达拉非（Adcirca），每种产品均针对不同的给药方式和患者需求。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票超过联合治疗</li>
<li>巴菲特花了 60 年忽视科技，账单即将到来</li>
<li>对黄金感到兴奋但不确定其走势？试试这三种方法</li>
<li>美元处于三年低点：三家出口商悄然印钞</li>
<li>水务基础设施：为什么这个乏味的行业可能会变得令人兴奋</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VVRIUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VVRIUg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在联合治疗吗？</h2>
<p>在考虑联合治疗之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而联合治疗并不在名单上。</p>
<p>虽然联合治疗目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

联合治疗

<p>M&T Bank Corp 在第四季度将其在联合治疗公司（NASDAQ:UTHR）的股份增加了 171.6%，目前持有 3,142 股，价值 153 万美元。其他机构投资者也增加了他们的持股。尽管最近的财报未能达预期，但由于联合治疗的产品线和增长潜力，市场对其持积极态度。分析师的看法不一，目标价格范围从 516 美元到 660 美元不等。UTHR 股票开盘价为 564.94 美元，市值为 239.8 亿美元，市盈率为 20.85</p>

<p>M&amp;T Bank Corp boosted its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 171.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,142 shares of the biotechnology company's stock after buying an additional 1,985 shares during the period. M&amp;T Bank Corp's holdings in United Therapeutics were worth $1,531,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>M&amp;T Bank Corp 在最近向证券交易委员会提交的文件中表示，在第四季度将其在联合治疗公司（NASDAQ:UTHR - 免费报告）的持股比例提高了 171.6%。该公司在此期间购买了 1,985 股后，持有这家生物技术公司的 3,142 股股票。M&amp;T Bank Corp 在联合治疗公司的持股在最近一个季度末价值为 1,531,000 美元。</p>
</div><ul>
<li>The Top 3 Stock Picks at the World’s Greatest Hedge Fund</li>
</ul>
<div class="lb-trans"><ul>
<li>全球最大对冲基金的三大股票推荐</li>
</ul>
</div><p>Other institutional investors and hedge funds have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB raised its holdings in United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock valued at $37,000 after buying an additional 49 shares during the period. Harbor Capital Advisors Inc. purchased a new stake in United Therapeutics in the 4th quarter valued at about $48,000. Abich Financial Wealth Management LLC purchased a new stake in United Therapeutics in the 3rd quarter valued at about $44,000. WealthCollab LLC raised its holdings in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after buying an additional 38 shares during the period. Finally, Rakuten Securities Inc. raised its holdings in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after buying an additional 46 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金最近也买卖了该公司的股票。威尔明顿储蓄基金协会 FSB 在第三季度将其在联合治疗公司的持股提高了 125.6%。威尔明顿储蓄基金协会 FSB 现在拥有 88 股这家生物技术公司的股票，价值 37,000 美元，此前在此期间又购买了 49 股。哈伯资本顾问公司在第四季度购买了价值约 48,000 美元的联合治疗新股份。Abich Financial Wealth Management LLC 在第三季度购买了价值约 44,000 美元的联合治疗新股份。WealthCollab LLC 在第二季度将其在联合治疗公司的持股提高了 55.9%。WealthCollab LLC 现在拥有 106 股这家生物技术公司的股票，价值 30,000 美元，此前在此期间又购买了 38 股。最后，乐天证券公司在第二季度将其在联合治疗公司的持股提高了 76.7%。乐天证券公司现在拥有 106 股这家生物技术公司的股票，价值 30,000 美元，此前在此期间又购买了 46 股。目前 94.08% 的股票由对冲基金和其他机构投资者持有。</p>
</div><p>Get <strong>United Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>联合治疗</strong> 的提醒：</p>
</div><h2>Key United Therapeutics News</h2>
<div class="lb-trans"><h2>联合治疗的关键新闻</h2>
</div><p>Here are the key news stories impacting United Therapeutics this week:</p>
<div class="lb-trans"><p>以下是本周影响联合治疗的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Investors are focusing on United Therapeutics’ pipeline and growth catalysts, especially encouraging Tyvaso data in IPF and optimism around ralinepag’s blockbuster potential, which could support future revenue growth. UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong Outlook</li>
<li>Positive Sentiment: Royal Bank of Canada kept an <strong>outperform</strong> rating and only slightly lowered its price target to $701 from $707, signaling continued confidence in upside from current levels. RBC lowers price target on UTHR</li>
<li>Neutral Sentiment: United Therapeutics held its Q1 2026 earnings call, which investors are likely parsing for commentary on Tyvaso, ralinepag, and the company’s growth outlook. Q1 2026 Earnings Call Transcript</li>
<li>Negative Sentiment: Q1 results missed estimates, with EPS of $5.82 versus expectations of $7.00 and revenue of $781.5 million versus $797.4 million expected; revenue also declined 1.6% year over year. Q1 2026 Financial Results</li>
<li>Negative Sentiment: Insider selling may be weighing on sentiment: CEO Martine Rothblatt sold 9,500 shares and EVP Paul Mahon sold 8,300 shares, both sizable reductions in their holdings. Rothblatt SEC filingMahon SEC filing</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：投资者关注联合治疗的产品管线和增长催化剂，尤其是关于 IPF 的积极 Tyvaso 数据和对 ralinepag 的巨大潜力的乐观情绪，这可能支持未来的收入增长。UTHR 第一季度业绩未达预期，股价因强劲前景而上涨</li>
<li>积极情绪：加拿大皇家银行维持 <strong>跑赢大盘</strong> 的评级，仅将其目标价从 707 美元略微下调至 701 美元，表明对当前水平的上行潜力仍然充满信心。RBC 下调 UTHR 的目标价</li>
<li>中性情绪：联合治疗召开了 2026 年第一季度的财报电话会议，投资者可能会关注关于 Tyvaso、ralinepag 和公司的增长前景的评论。2026 年第一季度财报电话会议记录</li>
<li>消极情绪：第一季度业绩未达预期，EPS 为 5.82 美元，低于预期的 7.00 美元，收入为 7.815 亿美元，低于预期的 7.974 亿美元；收入同比下降 1.6%。2026 年第一季度财务结果</li>
<li>消极情绪：内部人士的卖出可能对情绪造成压力：首席执行官 Martine Rothblatt 卖出了 9,500 股，执行副总裁 Paul Mahon 卖出了 8,300 股，均为其持股的显著减少。Rothblatt SEC 文件 Mahon SEC 文件</li>
</ul>
</div><h2>United Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>联合治疗股票表现</h2>
</div><ul>
<li>Liquidia: Court victory the awakening of an industry giant?</li>
</ul>
<div class="lb-trans"><ul>
<li>Liquidia：法院胜利是行业巨头的觉醒？</li>
</ul>
</div><p>UTHR stock opened at $564.94 on Friday. The company's 50 day moving average price is $550.17 and its 200 day moving average price is $501.37. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35. The firm has a market capitalization of $23.98 billion, a price-to-earnings ratio of 20.85, a PEG ratio of 1.77 and a beta of 0.60.</p>
<div class="lb-trans"><p>UTHR 股票在周五开盘价为 564.94 美元。该公司的 50 日移动平均价格为 550.17 美元，200 日移动平均价格为 501.37 美元。联合治疗公司的 52 周低点为 272.12 美元，52 周高点为 609.35 美元。该公司的市值为 239.8 亿美元，市盈率为 20.85，PEG 比率为 1.77，贝塔值为 0.60。</p>
</div><p>United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts' consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $781.50 million for the quarter, compared to analysts' expectations of $797.40 million. During the same quarter in the previous year, the company posted $6.63 earnings per share. The firm's quarterly revenue was down 1.6% on a year-over-year basis. Equities analysts forecast that United Therapeutics Corporation will post 27.4 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>联合治疗（NASDAQ:UTHR - 获取免费报告）最近于 5 月 6 日发布了其财报。该生物技术公司报告第一季度每股收益为 5.82 美元，低于分析师一致预期的 7.00 美元（差额为 1.18 美元）。联合治疗的股本回报率为 19.24%，净利润率为 40.62%。该公司第一季度的收入为 7.815 亿美元，而分析师预期为 7.974 亿美元。在去年同期，该公司每股收益为 6.63 美元。该公司的季度收入同比下降 1.6%。股票分析师预测联合治疗公司在当前财年将发布 27.4 的每股收益。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师表示这两家中型生物技术公司具有 2 倍潜力</li>
</ul>
</div><p>UTHR has been the topic of several research analyst reports. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a report on Thursday. HC Wainwright boosted their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, March 31st. Bank of America boosted their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a &#34;neutral&#34; rating in a research note on Tuesday, March 31st. TD Cowen boosted their price target on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, March 30th. Finally, UBS Group boosted their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, March 5th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $619.42.</p>
<div class="lb-trans"><p>UTHR 一直是几份研究分析报告的主题。摩根士丹利在周四的报告中对联合治疗的股票设定了 516.00 美元的目标价。HC Wainwright 在 3 月 31 日的报告中将联合治疗的目标价从 600.00 美元提高至 660.00 美元，并给予该公司 “买入” 评级。美国银行在 3 月 31 日的研究报告中将联合治疗的目标价从 569.00 美元提高至 626.00 美元，并给予该股票 “中性” 评级。TD Cowen 在 3 月 30 日的研究报告中将联合治疗的目标价从 575.00 美元提高至 660.00 美元，并给予该股票 “买入” 评级。最后，瑞银集团在 3 月 5 日的研究报告中将联合治疗的目标价从 655.00 美元提高至 705.00 美元，并给予该股票 “买入” 评级。十一位投资分析师对该股票给予了买入评级，两位分析师对该公司的股票给予了持有评级。根据 MarketBeat，该股票的平均评级为 “适度买入”，共识目标价为 619.42 美元。</p>
</div><p><strong>Read Our Latest Analysis on UTHR</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 UTHR 的最新分析</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖情况</h2>
</div><p>In related news, CFO James Edgemond sold 10,000 shares of the company's stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $527.48, for a total value of $5,274,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares of the company's stock, valued at $9,956,712.48. This represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of the company's stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $474.65, for a total value of $10,679,625.00. The SEC filing for this sale provides additional information. Insiders sold 485,155 shares of company stock valued at $266,370,949 over the last ninety days. 10.30% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，首席财务官 James Edgemond 于 3 月 23 日星期一出售了 10,000 股公司的股票，交易平均价格为 527.48 美元，总价值为 5,274,800.00 美元。交易完成后，首席财务官直接持有 18,876 股公司的股票，价值为 9,956,712.48 美元。这代表其持股比例减少了 34.63%。此次出售在向 SEC 提交的文件中披露，相关文件可通过此链接获取。此外，首席运营官 Michael Benkowitz 于 2 月 9 日星期一出售了 22,500 股公司的股票，平均售价为 474.65 美元，总价值为 10,679,625.00 美元。SEC 对此次出售的文件提供了更多信息。在过去的九十天里，内部人士出售了 485,155 股公司股票，价值为 266,370,949 美元。目前，10.30% 的股票由公司内部人士持有。</p>
</div><h2>About United Therapeutics</h2>
<div class="lb-trans"><h2>关于联合治疗</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.</p>
<div class="lb-trans"><p>联合治疗公司 NASDAQ: UTHR 是一家生物技术公司，致力于开发和商业化独特产品，以应对危及生命的疾病。该公司的主要关注点是肺动脉高压（PAH），已推出多种疗法，旨在改善患者的功能能力和生活质量。其市场产品包括持续输注特瑞普利（Remodulin）、吸入特瑞普利（Tyvaso）、口服特瑞普利（Orenitram）和他达拉非（Adcirca），每种产品均针对不同的给药方式和患者需求。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than United Therapeutics</li>
<li>Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming Due</li>
<li>Excited About Gold But Unsure of Its Trajectory? Try These 3 Approaches</li>
<li>Dollar at a 3-Year Low: 3 Exporters Quietly Printing Money</li>
<li>Water Infrastructure: Why This Boring Sector Could Get Exciting</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过联合治疗</li>
<li>巴菲特花了 60 年忽视科技，账单即将到来</li>
<li>对黄金感到兴奋但不确定其走势？试试这三种方法</li>
<li>美元处于三年低点：三家出口商悄然印钞</li>
<li>水务基础设施：为什么这个乏味的行业可能会变得令人兴奋</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VVRIUg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=UTHR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in United Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在联合治疗吗？</h2>
</div><p>Before you consider United Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑联合治疗之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而联合治疗并不在名单上。</p>
</div><p>While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然联合治疗目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

M&T Bank Corp Raises Stock Holdings in United Therapeutics Corporation $UTHR

Market Beat

M&T Bank

Rakuten Group, Inc.

乐天集团(ADR)

加拿大皇家银行

Liquidia Tech

摩根士丹利

美国银行

M & T BANK CORP DEP SHS REPSTG 1/400TH INT PERP SER K

M & T BANK CORP PERP NON CUM PFD FIXED FLTG RATE SER H

M & T BANK CORP DEP SHS EA REP 1/400TH SHS SERIES J

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

M&T Bank Corp 增加了对 United Therapeutics Corporation $UTHR 的股票持有量